Abstract
Abstract
Background
Self-management support (SMS) forms a central pillar in the management of long-term conditions. It is firmly aligned with UK health policy but there is a paucity of evidence exploring how it is enacted in the context of neuromuscular diseases (NMDs). Bridges is a SMS programme originally developed in stroke. A new version of the programme (Neuromuscular Bridges) has recently been co-designed with people with lived experience of NMD and requires evaluation.
The implementation of SMS is inherently complex with potential barriers at the level of the patient, provider, and wider organisation. The success of implementing programmes can be highly dependent on context, indicating a rationale for considering implementation determinants at an early stage. This study aims to explore the feasibility of (1) delivering, (2) evaluating, and (3) implementing Neuromuscular Bridges at a specialist neuromuscular centre.
Methods
This study employs a hybrid II design underpinned by Normalisation Process Theory (NPT), which has been used prospectively to inform the implementation plan and will also inform the analysis. The feasibility of delivering, evaluating, and implementing Neuromuscular Bridges will be assessed using a single-arm pre-post design. In terms of delivery and evaluation, we will explore acceptability, demand within the service, performance of outcome measures, recruitment, and retention.
Implementation strategies have been selected from a refined taxonomy of strategies, mapped to NPT, and targeted at known barriers and facilitators at the specialist centre that were identified from preliminary stakeholder engagement activities. The impact of the strategy bundle on fidelity, acceptability, appropriateness, and adoption will be evaluated using qualitative interviews, administrative data, surveys, and a notes audit.
Conclusions
This this study will provide valuable feasibility data on a co-designed SMS programme for people with NMDs that will be used to inform a larger implementation study, requirements for embedding it in a specialist centre, and rollout to other specialist centres. Using hybrid methodology at the feasibility stage is unusual and this study will provide important insights into the usefulness of taking this approach at this point in the research pipeline.
Trial registration
ISRCTN Trial ID: ISRCTN14208138. Date registered: 18/08/2021.
Publisher
Springer Science and Business Media LLC
Reference86 articles.
1. Programme GE. Rare disease, genomics and the future - Genomics Education Programme [Internet]. Available from: https://www.genomicseducation.hee.nhs.uk/glossary/rare-disease/. [Cited 2021 Feb 20].
2. Pohlschmidt M, Meadowcroft R. Muscle disease: the impact- incidence and prevalence of Neuromuscular Conditions in the UK. London; 2010.
3. Winblad S, Jensen C, Månsson J-E, Samuelsson L, Lindberg C. Depression in Myotonic Dystrophy type 1: clinical and neuronal correlates. Behav Brain Funct. 2010;6(1):25 Available from: http://behavioralandbrainfunctions.biomedcentral.com/articles/10.1186/1744-9081-6-25. [Cited 2021 Feb 20].
4. Grootenhuis MA, de Boone J, van der Kooi AJ. Living with muscular dystrophy: health related quality of life consequences for children and adults. Health Qual Life Outcomes. 2007;5(1):31 Available from: https://hqlo.biomedcentral.com/articles/10.1186/1477-7525-5-31. [Cited 2021 Feb 20].
5. Elsenbruch S, Schmid J, Lutz S, Geers B, Schara U. Self-reported quality of life and depressive symptoms in children, adolescents, and adults with Duchenne muscular dystrophy: a cross-sectional survey study. Neuropediatrics. 2013;44(5):257–64.